Unicancer

This study tests whether adding the drug ivonescimab to standard chemotherapy can shrink tumors better than chemo alone in people with advanced stomach or gastroesophageal cancer. About 88 participants will receive treatment every two weeks. The main goal is to see how many patie…

This study tests a drug called zanidatamab in adults with certain advanced cancers (lung, endometrial, colorectal, head & neck, or sarcoma) that have a specific change in the HER2 gene. The goal is to see if the drug can shrink tumors. Participants receive the drug by IV every 3 …

This study aims to find the right dose of chemotherapy for people with digestive cancers who have a genetic condition called DPD deficiency, which makes standard chemo doses dangerous. About 400 participants will receive a reduced dose based on their DPD activity and be monitored…

This study looks at whether some women with early-stage triple-negative breast cancer can receive less chemotherapy. It includes two groups: one gets a combination of immunotherapy (pembrolizumab) and a lower dose of chemo, and the other gets no treatment after surgery, just regu…

This study tests whether adding darolutamide to standard hormone therapy (ADT) can slow cancer growth in men with metastatic prostate cancer who are not healthy enough for stronger treatments like chemotherapy. About 300 participants will receive either the drug combination or a …

This study tests if a new drug called ivonescimab works better than standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has worsened after initial treatment. About 72 patients who were part of a previous trial will receive either ivonescimab or chemother…

This study is for people with triple-negative breast cancer whose tumor did not completely disappear after initial chemotherapy plus immunotherapy. The goal is to see if adding two drugs—pembrolizumab and capecitabine—after surgery can help prevent the cancer from coming back. Ab…

This study tests whether a combination of two oral drugs (tucatinib and capecitabine) plus a chemotherapy given directly into the spinal fluid (trastuzumab) can help people with HER2-positive breast cancer that has spread to the lining of the brain and spinal cord. About 30 adult…

This study tests whether the immunotherapy drug dostarlimab works better than standard chemotherapy as the first treatment for people with advanced cancers that have specific genetic markers (dMMR/MSI). The cancers studied are rare types like pancreatic, stomach, and small bowel …

This study tests giving immunotherapy before surgery for cancers that haven't spread. It uses a quick blood and tumor test to match each person's treatment to their unique immune profile. The goal is to shrink tumors, boost the immune system, and lower the chance of cancer coming…

This study tests whether adding a liver-directed chemotherapy (GEMOX) to standard immunotherapy (durvalumab + tremelimumab) works better than immunotherapy alone for people with advanced liver cancer that has a high tumor burden. About 196 adults with liver cancer that has spread…

This study tests a different chemotherapy drug (trifluridine/tipiracil) for people with metastatic colorectal or gastroesophageal cancer who have a genetic condition (DPD deficiency) that makes standard chemo very toxic. About 73 participants will receive this drug along with oth…

This study tests whether injecting two immunotherapy drugs (ipilimumab and nivolumab) directly into melanoma tumors before surgery can shrink or eliminate the cancer while causing fewer side effects than standard IV treatment. About 50 adults with stage III melanoma that can be s…

This study tests whether the drug ribociclib can safely replace chemotherapy for women with a common type of early breast cancer (HR+ HER2-) that has an intermediate risk of coming back. About 3,900 participants will receive either standard chemotherapy followed by hormone therap…

This study tests an online program that teaches women at high or very high risk of breast cancer how to lower their risk through healthy lifestyle changes like diet and exercise. About 1,500 women aged 40-74 who already took part in a larger breast cancer screening study will be …

This study tests whether a digital platform called CUREETY TECHCARE can improve quality of life and reduce hospital visits for people with metastatic triple-negative breast cancer starting their first treatment. About 472 participants will either use the app to report symptoms an…

This study tests whether an artificial intelligence (AI) tool that predicts a woman's personal risk of arm lymphedema (swelling) after breast cancer radiation can help patients and doctors make better treatment choices. About 724 women with breast cancer who need radiation will b…

This study enrolls 400 adults with advanced breast, lung, stomach, or bladder cancer who are receiving antibody-drug conjugates (ADCs), a type of targeted therapy. Researchers will compare tumor samples taken before treatment and after the cancer progresses to identify genetic or…

This study is gathering medical information and biological samples from 400 adults with a specific genetic mutation (BRAFV600E) in advanced colorectal cancer. The goal is to learn how this cancer is treated in real-world settings and how long patients live. No new treatments are …

This study looks at whether measuring HPV DNA in the blood can help find throat cancer recurrence earlier in patients with HPV-related oropharyngeal cancer. About 420 participants will be followed after treatment to see if those with undetectable HPV DNA can safely have fewer che…